A Study of Anlotinib in Subjects With Advanced Malignancy

Status Completed

Clinical Trial Summary

Anlotinib is a tyrosine kinase inhibitors (TKI) with high effective in inhibiting angiogenesis and tumor cell proliferation by targeting VEGFR, PDGFR, FGFR and c-Kit. Previous phase I trial has shown the potency of anlotinib in treating patients with various cancer types who failed in standard treatment or lack proper treatment regimen. Here, a single center, single-arm, phase II study was conducted to further validate the efficacy and safety of anlotinib in these patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04216082
Study type	Interventional
Source	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact
Status	Completed
Phase	Phase 2
Start date	August 1, 2013
Completion date	August 1, 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00978926` - A Study of the Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies	N/A
Completed	`NCT01444404` - A Study of AMG 820 in Subjects With Advanced Solid Tumors	Phase 1
Completed	`NCT00428545` - Bevacizumab and Bortezomib in Patients With Advanced Malignancy	Phase 1
Completed	`NCT02743637` - A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors	Phase 1
Completed	`NCT01558817` - Changing the Paradigm of In-Hospital Cardiopulmonary Resuscitation With Informed Assent	N/A
Completed	`NCT01253707` - A Study of AMG 337 in Subjects With Advanced Solid Tumors	Phase 1
Completed	`NCT01723020` - A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma	Phase 1
Completed	`NCT00813384` - A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors	Phase 1
Completed	`NCT00974896` - QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors	Phase 1
Completed	`NCT02110355` - A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma	Phase 1
Completed	`NCT02978482` - A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies	Phase 1
Completed	`NCT00858377` - A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors	Phase 1
Terminated	`NCT02437916` - Safety Study of AMG 228 to Treat Solid Tumors	Phase 1
Terminated	`NCT01231347` - QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas	Phase 3
No longer available	`NCT01945164` - XL999 Administered Intravenously to a Subject With Advanced Malignancies	N/A
Completed	`NCT03875157` - Study of IBI318 in Participants With Advanced Malignancies	Phase 1
Completed	`NCT02016729` - A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia	Phase 1